Ugur Sahin: Latest News

All news where Ugur Sahin is mentioned

23.08.2022 / 03:45

Pfizer seeks OK of updated bivalent Covid-19 vaccine booster for fall

Omicron BA.1-adapted vaccine and pre-clinical and manufacturing data from the companies’ bivalent Omicron BA.4/BA.5-adapted vaccine to address the continued evolution of SARS-CoV-2. Pending authorization, the Omicron BA.4/BA.5-adapted bivalent vaccine will be available to ship immediately.

Albert Bourla Ugur Sahin India covid-19 vaccine

3 shots of Pfizer's COVID vaccine generate strong immune response in under 5 age group

Three doses of Pfizer's COVID-19 vaccine generate strong immune response in children under age 5, the company said on Monday adding, “it was well-tolerated by them clinical trial"

Ugur Sahin New York India Germany vaccine Immunic

COVID-19: Pfizer vaccine booster dose neutralizes Omicron variant, BioNTech CEO says

During a press conference in Mainz, Germany on Wednesday, BioNTech CEO Ugur Sahin said a third dose of the three-shot course of the Pfizer vaccine neutralized the Omicron COVID-19 variant in a laboratory test.

Ugur Sahin Germany covid-19 vaccine

Pfizer terms its Covid vaccine safe, effective for children aged 5-11 yrs

Pfizer and its German partner said in a joint statement on Monday.

Ugur Sahin Usa India Germany Eu covid-19 pandemic vaccine

BioNTech nearing request for approval of longer-lasting version of COVID vaccine

LONDON : BioNTech is working on getting approval for a version of its COVID-19 vaccine which can be stored in fridges of 2 to 8 degree celsius for up to 6 months, Chief Executive Ugur Sahin said on Tuesday."Our first formulation had to be stored and shipped at minus 80 degrees. We have now, in the meantime, a formulation which is not yet approved...

Ugur Sahin India covid-19 vaccine

BioNTech CEO says he expects Europe to reach herd immunity this summer

The CEO of BioNTech, which is working with Pfizer to produce one of the COVID-19 vaccines, Uğur Şahin said Wednesday he believed Europe would reach herd immunity in July or August at the latest.

Ugur Sahin covid-19 experts vaccine

Pfizer asks EMA to authorise jab for 12 to 15-year-olds

Pfizer and BioNTech have asked the European Medicines Agency to authorise their Covid-19 vaccine for 12- to 15-year-olds, a move seen as a crucial step toward achieving herd immunity.

Ugur Sahin Usa Germany Eu city Amsterdam Europe Coronavirus

BioNTech expects Covid vaccine trial results for babies by September

BERLIN: BioNTech expects results by September from trials testing the COVID-19 vaccine that it and Pfizer have developed in babies as young as six months old, German magazine Spiegel cited the company's CEO as saying."In July, the first results could be available for the five to 12 year olds, in September for the younger children," BioNTech Chief Executive Ugur Sahin told Spiegel.

Ugur Sahin India Germany city Berlin covid-19 testing vaccine

Europe will reach herd immunity this summer, BioNTech CEO says

coronavirus within the next four months, the head of German pharmaceutical company BioNTech, which developed the first widely approved COVID-19 vaccine with U.S.

Ugur Sahin Germany covid-19 Coronavirus CEO

BioNTech CEO says no evidence found regarding possible heart muscle inflammation from PFizer-BioNTech COVID-19 vaccine

BioNTech CEO Ugur Sahin said Wednesday that they were seeking more details on reports out of Israel of heart muscle inflammation following vaccinations with the PFizer-BioNTech COVID-19 vaccine, but said at this time they had not seen evidence or unusual incidence from other countries using the shot of such symptoms.

Ugur Sahin Israel covid-19 vaccine

Europe will reach herd immunity by August at the latest, BioNTech CEO says

BERLIN (AP) - Europe can achieve herd immunity against the coronavirus within the next four months, the head of German pharmaceutical company BioNTech, which developed the first widely approved COVID-19 vaccine with U.S.

Ugur Sahin Germany city Berlin covid-19 vaccine Coronavirus

BioNTech chief: Europe will reach herd immunity by August

BERLIN – Europe can achieve herd immunity against the coronavirus within the next four months, the head of German pharmaceutical company BioNTech, which developed the first widely approved COVID-19 vaccine with U.S. partner Pfizer, said Wednesday.

Ugur Sahin Germany city Berlin covid-19 vaccine Coronavirus

Pfizer, BioNTech: COVID vaccine effective in teens

Pfizer and BioNTech today announced that their COVID-19 vaccine was 100% effective and triggered a robust antibody response in a phase 3 US trial involving 2,260 adolescents 12 to 15 years old. The immune responses in that age-group, the companies said, exceeded those recorded previously among 16- to 25-year-olds.

Ugur Sahin Usa Britain covid-19 vaccine mask

Scientist behind Pfizer-BioNTech COVID-19 vaccine says next target is cancer

BERLIN - The scientist who won the race to deliver the first widely used coronavirus vaccine says people can rest assured the shots are safe, and the technology behind it will soon be used to fight another global scourge — cancer.Ozlem Tureci, who founded the German company BioNTech with her husband Ugur Sahin, was working on a way to harness the body's immune system to tackle tumors when they learned last year of an unknown virus infecting people in China.Over breakfast, the couple decided to apply the technology they'd been researching for two decades to the new threat.Britain authorized BioNTech's mRNA vaccine for use in December, followed a week later by the United States.

Ugur Sahin China Usa Germany Britain city Berlin covid-19 vaccine Coronavirus

The next target for scientist behind world's first coronavirus vaccine: Cancer

coronavirus vaccine says people can rest assured the shots are safe, and the technology behind it will soon be used to fight another global scourge — cancer.Ozlem Tureci, who founded the German company BioNTech with her husband Ugur Sahin, was working on a way to harness the body's immune system to tackle tumors when they learned last year of an unknown virus infecting people in China.Over breakfast, the couple decided to apply the technology they'd been researching for two decades to the new threat.Britain authorized BioNTech's mRNA vaccine for use in December, followed a week later by the United States.

Ugur Sahin China Usa India Germany Britain virus vaccine Coronavirus

Scientist behind coronavirus shot says next target is cancer

BERLIN – The scientist who won the race to deliver the first widely used coronavirus vaccine says people can rest assured the shots are safe, and the technology behind it will soon be used to fight another global scourge — cancer.

Ugur Sahin China Usa Germany Britain city Berlin virus vaccine Coronavirus

Germany's BioNTech racing to ramp up vaccine production

German firm BioNTech said Friday it was racing to ramp up production of its Covid-19 vaccine in Europe, to fill the "gap" left by the lack of other approved vaccines.

Ugur Sahin Usa Germany Britain Canada Eu World Coronavirus

From the lab to the jab: The BioNTech-Pfizer vaccine

It was over breakfast on the wintry morning of 24 January that Ozlem Tureci and her husband Ugur Sahin decided, "we need to fire the starting gun on this".

Ugur Sahin city Wuhan Germany World Coronavirus

4 drugmakers expect their vaccines to be effective against new Covid strain

COVID-19 vaccines will be effective against the new fast-spreading variant of the virus that is raging in Britain and are performing tests that should provide confirmation in a few weeks.Ugur Sahin, chief executive of Germany's BioNTech, which with partner Pfizer Inc, took less than a year to get a vaccine approved, said on Tuesday he expects its messenger RNA (mRNA) vaccine to still work well.Also Read | How hunger came back to haunt IndiaModerna Inc, Germany's CureVac and British drugmaker AstraZeneca Plc also believe their shots will work against the new threat that has sown chaos in Britain, prompting a wave of travel bans that are disrupting trade with Europe and threatening to further isolate the island country."Scientifically it is

Ugur Sahin Germany Britain virus vaccine strain

Drugmakers rush to test whether vaccines stop coronavirus variant

ZURICH/FRANKFURT : Drug makers including BioNTech and Moderna are scrambling to test their COVID-19 vaccines against the new fast-spreading variant of the virus that is raging in Britain, the latest challenge in the breakneck race to curb the pandemic.Ugur Sahin, chief executive of Germany's BioNTech, which with partner Pfizer took less than a year to get a vaccine approved, said on Tuesday he needs another two weeks to know if his shot can stop the mutant variant of the virus.Moderna expects immunity from its vaccine to protect against the variant and is performing more tests in coming weeks to confirm, the company said in a statement to CNN.

Ugur Sahin Germany Britain virus testing vaccine Coronavirus

BioNTech, Moderna rush to test whether vaccines stop coronavirus variant

ZURICH/FRANKFURT : Drugmakers including BioNTech and Moderna are scrambling to test their COVID-19 vaccines against the new fast-spreading variant of the virus that is raging in Britain, the latest challenge in the breakneck race to curb the pandemic.Ugur Sahin, chief executive of Germany's BioNTech , which with partner Pfizer took less than a year to get a vaccine approved, said on Tuesday he needs another two weeks to know if his shot can stop the mutant variant of the virus.Moderna expects immunity from its vaccine to protect against the variant and is performing more tests in coming weeks to confirm, the company said in a statement to CNN.

Ugur Sahin Germany Britain virus testing vaccine Coronavirus

Vaccine works against new UK Covid strain but 'more studies needed' says jab boss

The coronavirus vaccine does work against the UK's more transmissible variant of the disease, but more work is needed the head of one of the teams behind it has said.

Ugur Sahin Germany Britain vaccine strain Coronavirus

Vaccine boss insists jab works against UK Covid variant but 'more studies needed'

coronavirus vaccine works against the UK variant.However further studies will be needed to be completely sure, Ugur Sahin said.A new strain of SARS-CoV-2 has been identified in some areas of south England, which could be up to 70% more infectious than the typical virus.Countries across the globe shut their borders to Britain on Monday due to fears about a highly infectious new coronavirus strain, causing travel chaos and raising the prospect of food shortages in the United Kingdom.The discovery prompted the UK Government to cancel plans to relax social distancing restrictions over Christmas for those in affected areas.Mr Sahin told Bild TV that the German company would investigate the mutation in the coming days, but that he viewed the

Ugur Sahin Germany Britain vaccine strain Coronavirus

Pfizer partner BioNTech to boost covid vaccine capacity

Pfizer Inc. partner BioNTech SE is pursuing all its options to make more Covid-19 vaccine doses than the 1.3 billion the companies have promised to produce next year, according to the German company’s chief executive officer.The companies will probably know by January or February whether and how many additional doses can be produced, Ugur Sahin said Monday.

Ugur Sahin Germany covid-19 vaccine strain

Pfizer/BioNTech vaccine's 1st impact could be in April, COVID possibly under control 'by end of next summer'

General manager of Covid Recovery, Becky Board, administers the first Pfizer-BioNTech COVID-19 vaccine in London to patient George Dyer, 90, at Croydon University Hospital, at the start of the largest ever immunisation programme in the UK's history o (Photo by Dan Charity - Pool/Getty Images)With the distribution of the Pfizer/BioNTech vaccine and others, COVID-19 could be under control “by the end of next summer," the vaccine's creator told Fox News.In an interview conducted on the day of the Food and Drug Administration approval of the vaccine, BioNTech co-founder Prof. Ugur Sahin laid out a detailed timeline of what the next year could hold for global efforts to stop the pandemic.

Ugur Sahin Britain city London covid-19 pandemic vaccine Coronavirus

manchestereveningnews.co.uk

23.11.2020 / 16:12

56%

816

Everything we know about three coronavirus vaccines and when they will be available in the UK

the companies confirmed a higher efficacy rate of 95 per cent.

Ugur Sahin Britain covid-19 testing vaccine Coronavirus

Pfizer’s Covid-19 vaccine: All you need to know in 10 points

BioNTech-Pfizer vaccines could be available as early as Christmas this year, says BioNTech Chief Executive Ugur Sahin.The US Food and Drug Administration might grant emergency-use approval towards the end of the first half of December or early in the second half, the BioNTech Chief Executive added.Speaking to Reuters TV, Ugur Sahin said, "If all goes well I could imagine that we gain approval (from US FDA) in the second half of December and start deliveries before Christmas, but really only if all goes positively."Meanwhile, as the race for Covid-19 vaccine heats up, the World Health Organization's emergencies director warned saying that vaccines would not arrive in time to defeat the second wave of the novel coronavirus pandemic.Here is

Ugur Sahin Usa virus covid-19 vaccine Coronavirus

Pfizer Covid-19 vaccine deliveries could start 'before Christmas'

COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said on Wednesday.The efficacy of the shot was found to be consistent across different ages and ethnicities - a promising sign given the disease has disproportionately affected the elderly and certain groups including Black people.The U.S. Food and Drug Administration could grant emergency-use approval towards the end of the first half of December or early in the second half, BioNTech Chief Executive Ugur Sahin told Reuters TV.

Ugur Sahin covid-19 experts vaccine Volunteers

Coronavirus vaccine scientist aiming for 300m jabs with normality 'by next year'

The Daily Star's FREE newsletter is spectacular! Sign up today for the best stories straight to your inboxOne of the top scientists behind the Pfizer Covid-19 vaccine said the impact of the jab will kick in next summer and normality should return by next winter.Professor Ugur Sahin, chief executive of BioNTech, said it was “absolutely essential” to have a high vaccination rate before autumn next year to ensure a return to normal life next winter.He acknowledged that the next few months will be “hard” and that the promising preliminary results on the vaccine will not have an impact on infection numbers in the current wave.Interim results from the jab, created in partnership with Pfizer, were found to be more than 90% effective, the two firms

Ugur Sahin vaccine Government infection Coronavirus

Coronavirus expert explains 'key side effects' of vaccine

coronavirus vaccine has revealed there are no serious side effects of the jab. Ugur Sahin, chief executive of BioNTech, announced promising preliminary results of its vaccine with Pfizer - which was found to be 90% effective in preventing Covid-19 infection.

Ugur Sahin experts vaccine prevention Coronavirus

BioNTech scientist: Vaccine could halve coronavirus transmission

London: The new COVID vaccine being developed by Pfizer and BioNTech would begin to be delivered at the "end of this year, beginning of next year" if everything continued to go well, one of its creators said on Sunday.Last week, BioNTech and co-developers Pfizer said preliminary analysis showed their vaccine could prevent more than 90 per cent of people from getting Covid-19.

Ugur Sahin covid-19 vaccine BBC prevention

Coronavirus vaccine boss confident life will be back to 'normal' by this time next year

The boss of a drug company creating a highly-anticipated coronavirus vaccine expects the UK will return to a "normal" by winter next year.

Ugur Sahin Britain covid-19 vaccine prevention Coronavirus

Scientist behind coronavirus vaccine says first UK patients could get jab next month

The scientist behind the new coronavirus vaccine said the rollout could start as soon as the middle of next month.

Ugur Sahin Germany Britain vaccine Government patient Coronavirus

Pfizer-BioNTech covid vaccine trial remains on track, says CEO

Covid-19 vaccine candidate from Pfizer Inc. and BioNTech SE are in line with those seen in smaller early studies, a positive sign for one of the front-runners in the race for a shot.The partners haven’t had to stop their late-stage study over safety concerns, BioNTech Chief Executive Officer Ugur Sahin said in an interview.

Eli Lilly Ugur Sahin covid-19 president RNA vaccine track

Coronavirus vaccine can be fridge-stored for two weeks, expects BioNTech CEO

FRANKFURT : BioNTech expects that the experimental COVID-19 vaccine it is developing with Pfizer can be stored at refrigerator temperatures for at least two weeks, seeking to allay concerns that the compound may have to be deep-frozen.Speaking at an online media briefing on the purchase of an additional German production site, Chief Executive Ugur Sahin said tests have recently confirmed the genetic compound remains stable at 2 to 8 degrees Celsius for five days but he expects storability at those conditions to be two weeks or longer.He added that a good vaccine should have an efficacy of at least 70% to 75% for it to quell the pandemic and that was also the yardstick that BioNTech had set itself.BioNTech SE said it is buying a German

Ugur Sahin Germany covid-19 testing vaccine Coronavirus

pharmaceutical-technology.com

20.07.2020 / 14:43

81%

632

UK enters supply agreement for Pfizer and BioNTech’s Covid-19 vaccine

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The UK Government has signed an agreement with Pfizer and BioNTech for the supply of 30 million doses of the companies’ mRNA-based Covid-19 vaccine candidate, BNT162. Neither company divulged financial details of the deal, but the terms were said to be contingent on the delivery timing and the volume of doses.

Ugur Sahin Britain covid-19 vaccine Government

United States	Cases: 46 252 513 Deaths: 750 423 Recovered: 0
India	Cases: 34 321 025 Deaths: 459 652 Recovered: 0
Brazil	Cases: 21 835 785 Deaths: 608 235 Recovered: 0
United Kingdom	Cases: 9 215 683 Deaths: 141 607 Recovered: 0
Russia	Cases: 8 494 589 Deaths: 237 619 Recovered: 0